About Satellos
We ask different questions, follow the science wherever it leads, and move fast — because patients are waiting.
pathways for medicines
Satellos was founded on a simple but powerful idea: the greatest challenge in degenerative muscle diseases isn’t just muscle damage. It’s that the body can’t repair it.
Our understanding of this biology began with a discovery that healthy muscle repairs itself through asymmetric cell division. When that stem cell process is disrupted, muscle is unable to effectively repair itself.
That discovery led us to a broader insight: Different muscle diseases disrupt regeneration in different ways, but restoring muscle stem cell function may offer a common therapeutic strategy.
We’re developing forazapadin, an oral small molecule therapy designed to enhance the body’s natural ability to repair and regenerate muscle. By targeting AAK1, we aim to re-establish muscle stem cell asymmetric division (also referred to as stem cell polarity), which enables muscle repair and regeneration, as well as maintenance of the muscle stem cell pool for future repair and regeneration. We believe this regenerative approach has the potential to address multiple degenerative muscle diseases, including our first two clinical indications in Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.
Leadership
We’re a team of scientists, drug developers, and industry experts with deep expertise in rare disease, muscle stem cell biology, small molecule therapeutics, and drug development.
What brings us together is a shared belief: the key to treating degenerative muscle diseases lies in restoring the body’s natural ability to repair itself.
From our founding discoveries in muscle stem cell biology to advancing our investigational therapy in two clinical trials, we’re driven by a commitment to turn that belief into meaningful treatments for people living with degenerative muscle diseases.
Senior Leadership
Board of Directors